This short article outlines how thorough PK/PD modelling can significantly reduce the risk of failure in Phase 3 trials.
It examines how to aid in reducing the cost of late phase withdrawals by identifying new chemical entries (NCEs) that may fail and how Improved approaches to drug design and candidate selection have clearly improved in the PK properties of NCEs in recent years.
